SPGNY — Springer Nature AG & Co. KGaA/ADR

OTC · Unknown · Unknown · CIK 2042556 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Springer Nature AG & Co. KGaA, together with its subsidiaries, engages in the publishing business in Germany, the United Kingdom, the United States, and internationally. The company operates through three segments: Research, Education, and Health. It offers journals across various academic disciplines under the Nature Portfolio and Springer brand names; books in print and digital formats across various scientific disciplines, including monographs, textbooks, conference proceedings, handbook series, reference works, and briefs under the Springer and Palgrave Macmillan brand names; and support services to researchers, institutions, and industry professionals with AI-powered tools and services, such as AdisInsight, Springer Nature Experiments, protocols.io, and SpringerMaterials, as well as professional development and career services under the Nature Masterclasses, Nature Careers, and Nature Conferences brand names. The company also provides English language teaching content and national curricula learning resources under the Macmillan Education brand name. In addition, it offers specialist information and services to healthcare professionals under the Springer Medizin brand name; publications, learning solutions, and professional services to healthcare practitioners and students under the BSL brand name; content and services related to drug treatments, medical devices, and diagnostics under the Springer Health+ brand name; and Cureus Journal of Medical Science, a peer-reviewed OA medical journal. The company was founded in 1842 and is based in Berlin, Germany. Springer Nature AG & Co. KGaA operates as a subsidiary of GvH Vermögensverwaltungsgesellschaft Xxxiii mbH.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2025 5,098,500,000 302,200,000 3,264,500,000
Dec 2024 5,388,600,000 300,100,000 3,574,600,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-404,200,000
Inventory
$32,100,000
Receivables
ST Investments
$39,000,000
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,926,400,000
EBITDA
$708,800,000
Free Cash Flow
$295,137,504
Enterprise Value
$3,435,251,200
Total Cash
$269,700,000
Total Debt
$1,510,099,968
Shares Out
198,888,989
Trailing EPS
$0.95
Book Value
$5.97
ROE
18.5%
ROA
5.6%
Div Yield
4.43%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 1,847,100,000 404,400,000 68,300,000 5,388,600,000 3,574,600,000 531,200,000
Dec 2023 1,853,000,000 405,600,000 15,500,000 5,411,200,000 5,373,200,000 491,900,000

Peers — same industry

TickerNameMarket CapLastDaily %
SPY SPDR S&P 500 ETF TRUST $688.88B $750.59
KLAC KLA CORP $262.74B $2011.39
IBM INTERNATIONAL BUSINESS MACHINES CORP $235.62B $250.69
KXIAY Kioxia Holdings Corporation/ADR $231.81B $42.45
SMEGF Siemens Energy AG/ADR $180.38B $212.00

News headlines (Yahoo Finance, 1h cache)

Springer Nature AG & Co. KGaA (ETR:SPG) Passed Our Checks, And It's About To Pay A €0.83 Dividend
2026-05-24 08:43 · Yahoo
European Dividend Stocks To Enhance Your Portfolio
2026-04-21 10:32 · Yahoo
Springer Nature's CFO to Leave the Company by the end of 2026
2026-04-01 21:26 · Yahoo
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
2026-03-23 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.